N
Google TrendPANTHERS VS BLUE JACKETS (200+) — Gameday 7: Florida Panthers at Columbus Blue Jackets
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:panthers vs blue jackets200+posiciones de atlético de madrid contra manchester united5000+devils vs red wings2000+lioness season 35000+tresoldi200+street fighter movie early reviews2000+luis díaz200+halle berry child custody hearing200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Two Years of Ofatumumab R" (18 stories)

Top Headline Story

A five-year analysis estimated disability progression at 9.4% with BRIUMVI, versus 17.9% with ofatumumab
Lead StoryStock Titangeneral
1d ago

A five-year analysis estimated disability progression at 9.4% with BRIUMVI, versus 17.9% with ofatumumab

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPLTlUVmhVQnIwMUs5UVdHUy1ueEgtZ3V4LTE4UjVRTGJrakNQV0FQaDZ2QW5UWmRyMVRNXzZWTGhSWGJOaWw3VUh2M01EVXVXbnV5SXNLd2h0Q1JFVGZUcDBWdy1KTkNLcVV2Rms2bGpVVVZCTHk3Qmlkb0JsNjBWbUgxb2VuM2l4QVFxZVJkNkFPVGlDa3BnZDRXdzFTNWk0THVpQXhxYThxcVEzTVd6a2x5d084emoz?oc=5" target="_blank">A five-year analysis estimated disability progression at 9.4% with BRIUMVI, versus 17.9% with ofatumumab</a>  <font color="#6f6f6f">Stock Titan</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+19m ago

panthers vs blue jackets

Gameday 7: Florida Panthers at Columbus Blue Jackets

Filter stories
5000+29m ago

posiciones de atlético de madrid contra manchester united

Atlético 2 - 0 Manchester United: resumen, goles y resultado de la Champions League

Filter stories
2000+29m ago

devils vs red wings

Roster Changes for Devils vs. Red Wings | PREVIEW | New Jersey Devils

Filter stories
5000+29m ago

lioness season 3

Thank Zoe Saldaña for ‘Lioness’ Season 3’s Perfect Cliff-Hanger

Filter stories

Search Results for "Two Years of Ofatumumab R"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

17 stories displayed
Two Years of Ofatumumab Reshapes the Immune Landscape in Multiple Sclerosis
Bioengineer.orgworld

Two Years of Ofatumumab Reshapes the Immune Landscape in Multiple Sclerosis

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOOFgyT29waXNBSjNxWVhJNXROQ3VDdXhyeXE0SFpadVIyNUM3RGFHUkhhUkhrTXZzLUxBVGpXbTRuZWFTeU1UZ1FYSHJubURibW50OXVGVGNfbjFFeEhhOVFHVXJaSnNwVDFvbXNzeHQ2Vmc1NTlkNWp3WVNyZDFaX2FpTXZhN1hKQ1JmQ1Zxek5DcjRISU5seE9MYXN3UldpdHc?oc=5" target="_blank">Two Years of Ofatumumab Reshapes the Immune Landscape in Multiple Sclerosis</a>  <font color="#6f6f6f">Bioengineer.org</font>

Read Full StoryMore like this
Case Report: Ofatumumab for the treatment of refractory anti-NMDAR-positive autoimmune encephalitis
Frontiersworld

Case Report: Ofatumumab for the treatment of refractory anti-NMDAR-positive autoimmune encephalitis

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNOTVkRDZTaDB4ejNDaVNfeEhjWDJRVzFndTlfOFNWNjNLODE1QjJZRmdTemhFak0xQk5JeEljbENOb0RnZHNPUXROdXBETjY3cFZaSXpBMG9nY0lxVFpob3lsRzhsVnE5Wm5LbHVoVmJVRWVhV2w4NzNXcEJ0VXdhOEFHekhxd1doWEliRVNZY1l4Zw?oc=5" target="_blank">Case Report: Ofatumumab for the treatment of refractory anti-NMDAR-positive autoimmune encephalitis</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Ofatumumab versus Teriflunomide in Multiple Sclerosis
NEJMworld

Ofatumumab versus Teriflunomide in Multiple Sclerosis

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9wUGttenYyWVhxRnFOU1J3VFNRTzAzd0JlTDZ2OGd3S08yTnV6bVEtRzhlNlBiNnVXMHJfby15M2Jfam1TTHpBX29nMEYtWU1LaTdmQlRZbEstZkFpTUZSRg?oc=5" target="_blank">Ofatumumab versus Teriflunomide in Multiple Sclerosis</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
Novartisgeneral

Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNeHVyVXBBdi1qX2tqell1R2FHMUVYN0p6eG96b09NcTFCSnI4eElkQ2pLQXdFakJwdXA1bFc2Qzl0ZkNaUW8xdTFjOVlHR2FHN1ZBMy12RGlDYVBQOFdqc2FhWVdqdkFaSVFjZnRENkE2cHlJNTE1NVZBdDZrMGlObGJFOGJ2RXBPX05fc3ZrZnBmLWdGR1I2MjRoOEJzbkRhMmV3VVU3RDg5OUFzSzZpV1R1Y2EwWmV4bWRfT0FlNGJJSHNpLVNvOHM4eFo2cm5hbDZXOE1lUW1zdmJicGZjUTY2aEpCelNLUGo0?oc=5" target="_blank">Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies</a>  <font color="#6f6f6f">Novartis</font>

Read Full StoryMore like this
Pregnancy Outcomes in Ofatumumab-Treated Women Appear Consistent With General Population Rates
NeurologyLivegeneral

Pregnancy Outcomes in Ofatumumab-Treated Women Appear Consistent With General Population Rates

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQbDlkQUhxd2lVTGZkck9qVkpqOEdtVHhVZDZkbkdSUm9DS0Y1d2tNSS1QN3dRMHBYVVNUUUs4MUxsY2E4Y0RCdVU0M01NQm05Ymd5b2RHdDY4SkR2YVlwWklvTzM0bzhyZTJjNXU1V0U5Q181TG01Z1VTMExLR1NVYk8tLXBSVnJrMnlqaUZPV0t4MGhBeHJUTFRaeFBkMVQ4WGZSN2w5WXhTQWk5MUVldW00R2xBN3ZST1R3eXNB?oc=5" target="_blank">Pregnancy Outcomes in Ofatumumab-Treated Women Appear Consistent With General Population Rates</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group
The Lancetgeneral

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQNWxaaEVUa0F4OVcwVGZZQzQwRDZVVHFOc29nTW1LbkRDdEZLLUFuYmJXSXNaTnJud3VBZjYtUTc0WTFUN3VZYnRFZ2JYazlOOVJGdEh4Zkg5cTZGUEcybWtLenA3NWJwRG9XTXNTSzJZVkhUVk81bEE2V0RQZTJRWGdETFRFZGwwdXF3?oc=5" target="_blank">Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Evidence favors lower-dose R-CHOP for fit, very elderly DLBCL patients
MDEdgegeneral

Evidence favors lower-dose R-CHOP for fit, very elderly DLBCL patients

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOLVZKemkza2UzYWZFYmwxVVY5XzhfR2tTUDJjX0xMM29yb1RGS09FeTVzTmRmSW5ra0ZGd3pDaVlkX1VRbnVnMmgxZ2lDbEFsbHY1dE00RWRNRVRZZ0l2MXgtc2luWmlNYlJNdVlUQjJjZkRSMDFPRkE1cExiQWhsanFKSmxhVXU5VGFCNjdjMHpiTnpmS1dsTkMxVlBkMWR2VWJNcUZVNlViWG1yTTZtUWlSRnhuUQ?oc=5" target="_blank">Evidence favors lower-dose R-CHOP for fit, very elderly DLBCL patients</a>  <font color="#6f6f6f">MDEdge</font>

Read Full StoryMore like this
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
Naturegeneral

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE01aUlPSzdtMW9vOVNOdW13LXFTa2Nqa2VNQXBWWjcwbE5vMThaV2p2dHBRaG5zd2YwMzFWU2RpaXJPeTlZOVJ3RlZTYkRsZEJnN2N6ZQ?oc=5" target="_blank">Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura
Frontiersgeneral

Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQUFRsZ19xNmJadndaZmoxTU9zOUp1TnI3MGdHRHZyT3R1eFJ6NXBEZlIycUVXWV9NbGpxMWZ0bXFEQ3FneVRZbFJYS3A1cjdhTmt2U1JiV3BwemxLbHZPYVNrMi1xUE9VWDhpcXRLWW5MUjdJd0hWUEdyY3FTSjBJX0Ftbjl5azBNb0dPYkFUdmdZQQ?oc=5" target="_blank">Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
NEJMgeneral

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBMbWR0b3Q3bHkzM0lRVGFEejVuekdtQjZUMEtscUZYbDU4RElVeTNUN3JwV1k4aTFjZDZLdEpwYkZUYWNBUURzWDMyV3pUOTNYMXFkRmhYcWZ0XzZqX25GZg?oc=5" target="_blank">Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Official Janssen Oncology Online Press Kit for the 53rd ASCO Annual Meeting
MultiVugeneral

Official Janssen Oncology Online Press Kit for the 53rd ASCO Annual Meeting

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNallUNUZFZ3ZnZXV1ZGtvSlVhSDVCd2NGLTJnU2ZXUGJQeWJqc0s5SVNwbkFpYzNKa0RwRVZlR1lTT2IwbDhRVEV5eHBxVWFOQ2tPTFRxeGQySzh5RlBqS2hfZ1lkTUlBb2l6NHlwZlp1bV9ybFhWdGZxZ09VVXc4UmFJZTV1Njl1Nnc?oc=5" target="_blank">Official Janssen Oncology Online Press Kit for the 53rd ASCO Annual Meeting</a>  <font color="#6f6f6f">MultiVu</font>

Read Full StoryMore like this
Case Report: Severe psoriasis skin lesions following ofatumumab treatment for multiple sclerosis
Frontiersgeneral

Case Report: Severe psoriasis skin lesions following ofatumumab treatment for multiple sclerosis

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPWHhUWmF5VEdlMldTOW0wazA5dWtPT3UxdWRJcld3QnNNWTdBamVnYXBVNlA2S25jM1pfVlo3eDdDN0JQWUhaQzJJdGlrR1lYMXg5cW80akc2N0hhZ28xazhfZVJJdzhlOUZQUVFhV1FCbzhsbmdIUFZPVFEtQzlNNXhKYk43ZUtzY0ZMMG5jSFNoUQ?oc=5" target="_blank">Case Report: Severe psoriasis skin lesions following ofatumumab treatment for multiple sclerosis</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Ofatumumab for Rituximab-Resistant Nephrotic Syndrome
NEJMgeneral

Ofatumumab for Rituximab-Resistant Nephrotic Syndrome

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1GNlZqRTVjTEhpellxZW1tVVJCNGV4cWlIanpoZ0tnZ3kwdWxDb2xZc045UFRmMjdkLTRvcjk4UEM4MjcwY3dFSFdHaEZoNDNuTmRsb0xlOTJnNEhUZlo0?oc=5" target="_blank">Ofatumumab for Rituximab-Resistant Nephrotic Syndrome</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
Frontiersgeneral

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPTkhHNjdWUmV2bWVnQ3BlNDVBT3Ribml5REt2ZWFOakZjaWpLbG1iSWRNZ2ppVU9yMkd1NVpDbWMxdWM2emxLb0w0alFlaFhsNUVlQXJoU3FCcHNmd1JpUDl4NWFLWEljdE43VDRpa281S0JjakllSy1nM2N4WkJwQXdoNzNYS1FNcTVmdTd3ZVpOZw?oc=5" target="_blank">Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Ofatumumab successfully treats myelin oligodendrocyte glycoprotein antibody-associated disease accompanied by Epstein-Barr viral infection: a case series
Frontiersgeneral

Ofatumumab successfully treats myelin oligodendrocyte glycoprotein antibody-associated disease accompanied by Epstein-Barr viral infection: a case series

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOSUxFSkE4YTlxRHIyVzQ5b0dKN0YzTmhmbW5vaHN3TmhHUVRvbnk4OWJNbHFpTGxVLVZ4UEMtRWxCeG9oT3JXRGJsbDgwaVZaWF9kandWZkhlM1cxNGFKcnFnX2hVVlJxRWlRMzhveGxESElVSlZrRE9TNXR5UmRFRktHR1hoa083UFFFUnU5OENBQQ?oc=5" target="_blank">Ofatumumab successfully treats myelin oligodendrocyte glycoprotein antibody-associated disease accompanied by Epstein-Barr viral infection: a case series</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Antibody-mediated cell depletion therapies in multiple sclerosis
Frontiersgeneral

Antibody-mediated cell depletion therapies in multiple sclerosis

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNcXlaTXVNY05FRUQyMUhnem5zenZPVktHLWhRNzVwbzFDTngxa09hWnhjNGlzYkd4OFRwb3lqYmNwTkdRZWtaYW9NcEFnT0tXdmVMYzNlQzhsNmloNUNWQlFtVzhOcGR6MFF1MFo4MDBxaV9aMi1TN3lnWHNyTVJQZWVCaHBHMWVyaWU1QlZOc1Y?oc=5" target="_blank">Antibody-mediated cell depletion therapies in multiple sclerosis</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
The case report of MOG and NMDAR IgG double positive encephalitis treated with subcutaneous ofatumumab
Frontiersgeneral

The case report of MOG and NMDAR IgG double positive encephalitis treated with subcutaneous ofatumumab

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPd0VTVklLVlpaNmxseUFxcnZpTTlwWDVjcFFCdGlkWk96aG1FRUtYLTNWT18yV0hWZHhqNG1ESWdUZUgzaHR2WlAwWU9XbW5XSnlaY29fU1VsY1hjbGNBWHZfVnZsUEhZMGZvU00zZENXZ1ZHN3lyYjNLa2h3TlFMQzAta0lad2NGTTJNQkloTURRZw?oc=5" target="_blank">The case report of MOG and NMDAR IgG double positive encephalitis treated with subcutaneous ofatumumab</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
"Two Years of Ofatumumab R" — Live Google News Trends & Headlines